Sreejesh Sreedharanunni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sreejesh Sreedharanunni has a total of 295 co-authors. Here are the top co-authors by number of shared publications:
Man Updesh Singh Sachdeva
Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
27 shared publicationsPankaj Malhotra
Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
22 shared publications- Neelam Varma
Department of Hematology Post Graduate Institute of Medical Education and Research Chandigarh India
14 shared publications Arihant Jain
Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
13 shared publicationsPraveen Sharma
Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
13 shared publications- Prashant Sharma
Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
12 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Blood Research
- Vol. 61 (1) , 58
Telomere length analysis using qPCR in aplastic anemia: prevalence and predictive value for germline mutation status
- 1 October 2026
- Published by Springer Nature in Blood Research
- Vol. 61 (1) , 58
Open AccessTelomere length analysis using qPCR in aplastic anemia: prevalence and predictive value for germline mutation status
- Open Access
- 24 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Mutational Profile and Genetic Classification of Diffuse Large B-Cell Lymphoma in an Indian Patient Cohort
From the 8th International Cancer Congress
- 24 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessMutational Profile and Genetic Classification of Diffuse Large B-Cell Lymphoma in an Indian Patient Cohort
From the 8th International Cancer Congress
- 19 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1616-1626
ICH - ISHBT Recommendations on Synoptic Reporting of Bone Marrow Biopsy
- 19 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1616-1626
ICH - ISHBT Recommendations on Synoptic Reporting of Bone Marrow Biopsy
- 19 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1594-1605
ICH-ISHBT Recommendations on Synoptic Reporting of Peripheral Blood Smears (PBS)
- 19 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1594-1605
ICH-ISHBT Recommendations on Synoptic Reporting of Peripheral Blood Smears (PBS)
- 13 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1606-1615
ICH-ISHBT Recommendations On Bone Marrow Aspiration/Imprint Smear Synoptic Reporting
- 13 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1606-1615
ICH-ISHBT Recommendations On Bone Marrow Aspiration/Imprint Smear Synoptic Reporting
- Open Access
- 16 May 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 21
VEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort
Background: VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the UBA1 gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome. Materials and methods: A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization. Results: A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T>C Exon 3) (55%), p.Met41Val (c.121 A>G Exon 3) (27%), p.Met41Leu (c.121 A>C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G>C) (9%). p.Met41Val is associated with inferior overall survival (OS). Conclusion: This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.
- 16 May 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 21
Open AccessVEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort
Background: VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the UBA1 gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome. Materials and methods: A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization. Results: A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T>C Exon 3) (55%), p.Met41Val (c.121 A>G Exon 3) (27%), p.Met41Leu (c.121 A>C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G>C) (9%). p.Met41Val is associated with inferior overall survival (OS). Conclusion: This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.